Dr. Neuner’s research primarily focuses on clinical epidemiology, health services and quality of care among two groups: women with fractures or fracture risk factors and breast cancer survivors. She has analyzed large national databases of Medicare recipients to examine screening practices and has identified that older, highest-risk patients have a much lower chance of receiving osteoporosis screening. She has also identified racial and socioeconomic disparities in testing even after hip fracture. Dr. Neuner has used physician and patient surveys to examine decision making regarding fracture prevention. Along with MCW and University of Wisconsin-Milwaukee (UWM) co-investigators,she is beginning an intervention to improve osteoporosis and osteoarthritis decision making through a patient portal into the electronic medical record.
Her work with breast cancer survivors has also examined large cohorts of women, both from nationwide cancer registries and a national sample of surveyed women. Most recently she has focused on the pharmacoepidemiology of bony fractures and osteonecrosis of the jaw among these women. Her team recently reported an increased hip fracture risk among women using aromatase inhibitors in a large real-world cohort, a risk that was not identified in randomized trials. They are currently examining chemotherapy and bisphosphonate effects on a number of outcomes, with a focus on timing and dose.